Yingke PE, CSPC, Hillhouse Capital, Chinese Academy of Sciences Venture Capital, Atlas Capital, Boyuan Capital, Elite Capital, and Daehwa Pharmaceutical also participated in the round. The post China’s Huagai Capital leads $146m round in HaiHe Biopharma appeared first on DealStreetAsia.